Serum Markers as a Predictor of Response Duration and Patient Survival After Hormonal Therapy for Metastatic Carcinoma of the Prostate

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

1989 • 1,494 citations

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

1991 • 1,273 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)

1993 • 259 citations

Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial

1993 • 182 citations

The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

1992 • 175 citations

Chemotherapy of advanced prostatic cancer Evaluation of response parameters

1976 • 130 citations

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1992 • 95 citations

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta‐analysis of seven randomized double‐blind trials (1056 patients)

1994 • 80 citations

Prostatic acid phosphatase in 1993. Its limited clinical utility.

1993 • 67 citations

PROSTATIC ACID PHOSPHATASE IN 1993

1993 • 57 citations

Chemotherapy of advanced prostatic cancer.

1977 • 26 citations

Audit and its Impact in the Management of Early Prostatic Cancer

1993 • 12 citations

FUTURE DIRECTIONS IN TUMOR MARKER TECHNOLOGY FOR PROSTATE CANCER

1993 • 8 citations

Future directions in tumor marker technology for prostate cancer.

1993 • 8 citations

Management of pain and other symptoms of advanced prostatic cancer.

1988 • 7 citations

Management of pain and other symptoms of advanced prostatic cancer.

1988 • 4 citations